MAPT and Alzheimer disease: This hypothesis agrees with the observations that clearance of amyloid-beta using specific antibodies lessens tau pathologies in a transgenic AD mouse model expressing both mutant APP and Tau [77], or conversely that amyloid burdens in mutant tau mice lead to enhanced tau pathologies [78, 79].